IMMUNO-model
COST ACTION CA21135
Modelling immunotherapy response and toxicity in cancer
Foster research and innovation in the field of preclinical immuno-oncology models
IMMUNO-model
COST ACTION CA21135
Foster research and innovation in the field of preclinical immuno-oncology models
About
The COST Action IMMUNO-model CA21135 aims to foster research and innovation in the field of preclinical immuno-oncology models with the ultimate goal of advancing in the treatment of cancer patients by improving their outcomes and quality of life.
Structure
IMMUNO-model will be composed of five Working Groups (WGs) that will work on the implementation of the Action.
The main goals of WG1 will be to foster the development and optimization of in vitro and ex vivo models for immuno-oncology research, and to promote know-how sharing, protocol standardization, and the creation of user guidelines on these models.
Experimental animals are the most widely used preclinical models to assess immunotherapy response. However, some critical issues on their generation and use remain to be addressed. The main goal of WG2 will be to foster the collaboration and knowledge exchange between researchers in the field to promote the design of new in vivo models in immunotherapy and establish standard protocols and approaches for their use.
Solid and hematologic tumours differ importantly not only in their biological and molecular features, but also in the way they respond to immunotherapy. While ICIs have been proven efficient for the treatment of solid tumours, their use in hematologic malignancies is lagging behind. Cellbased immunotherapies instead have shown more promising results in blood cancers than in solid tumors. These differences speak to the need of creating WGs that specifically focus on immunotherapy research in solid or hematologic tumors and address the most relevant questions within those to fields.
Hematologic malignancies have always been at the forefront in the application of immunotherapy against cancer. Current research in the field is mostly focused on developing novel CAR-T-based strategies, improving the therapeutic effects of ICIs and identifying new immunotherapy targets for the treatment of blood cancers.
This WG will have the mission of promoting the internal communication within the Network (among WGs, between WGs and TGRCs, and between the TGRCs and the MC), and beyond the Network (general public, patients associations, potential industrial participants, policymakers, clinicians, ECIs, etc).
Patients
Immunotherapy (IT) has now revolutionized the way cancer patients are treated. You may wonder What about my cancer? Can I benefit from this treatment?
Join us
The COST Action IMMUNO-model welcomes research-active scientists working in the field.
If you would like to join this COST Action please ensure that you read the guidance notes published on the COST website. You can find full documentation regarding general rules and guidelines for COST Actions at www.cost.eu/participate